We agree with Bergua et al.1 on the possible superior efficacy of combination therapy treatment with rituximab and chemotherapy in CD20-positive multiple myeloma, with respect to rituximab alone, due to its synergism with many cytotoxic drugs. Nevertheless, the intention of our case report2 was to highlight a possible role of subsequent immunotherapy after debulking with chemotherapy to reduce the residual disease.
Gozzetti, A., Fabbri, A., Lazzi, S., Bocchia, M., Lauria, F. (2008). Reply to “Rituximab activity in CD20-positive multiple myeloma”. LEUKEMIA, 22(5), 1083-1083 [10.1038/sj.leu.2405011].
Reply to “Rituximab activity in CD20-positive multiple myeloma”
GOZZETTI, ALESSANDRO;LAZZI, STEFANO;BOCCHIA, MONICA;LAURIA, FRANCESCO
2008-01-01
Abstract
We agree with Bergua et al.1 on the possible superior efficacy of combination therapy treatment with rituximab and chemotherapy in CD20-positive multiple myeloma, with respect to rituximab alone, due to its synergism with many cytotoxic drugs. Nevertheless, the intention of our case report2 was to highlight a possible role of subsequent immunotherapy after debulking with chemotherapy to reduce the residual disease.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Reply to ‘Rituximab activity in CD20-positive-Gozzetti-2008.pdf
non disponibili
Descrizione: Commento
Tipologia:
PDF editoriale
Licenza:
NON PUBBLICO - Accesso privato/ristretto
Dimensione
60.45 kB
Formato
Adobe PDF
|
60.45 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
Utilizza questo identificativo per citare o creare un link a questo documento:
https://hdl.handle.net/11365/29312